Comparison of Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy

Status: Recruiting
Location: See location...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients. Since the exposure of subendothelial tissue to the blood flow after CE, the coagulation cascade can be activated, resulting in the increased risk of graft failure. Therefore, anticoagulation with warfarin in this group of patients might be beneficial. However, evidence is limited. This study aims to compare the clinical outcomes between dual antiplatelet therapy with or without warfarin after CE+CABG.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adult patients with diffuse coronary artery disease undergoing CE+CABG during the study period.

• No contraindications for both dual antiplatelet therapy and anticoagulation therapy with warfarin.

• Must be able to swallow tablets after the surgery.

Locations
Other Locations
China
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING
Beijing
Contact Information
Primary
Xieraili Tiemuerniyazi, M.D.
tiemuernyz@mail2.sysu.edu.cn
010-88322265
Time Frame
Start Date: 2023-04-11
Estimated Completion Date: 2025-10-31
Participants
Target number of participants: 202
Treatments
Other: DAPT
Comparison group: dual antiplatelet only
Experimental: DAPT+warfarin
Intervention group: dual antiplatelet combined with warfarin
Sponsors
Leads: China National Center for Cardiovascular Diseases

This content was sourced from clinicaltrials.gov